Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression Under B-Cell Depleting Treatment in Multiple Sclerosis

Objective: To investigate the longitudinal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) levels in people with multiple sclerosis (pwMS) under B-cell depleting therapy (BCDT) and their capacity to prognosticate future progression independent of relapse activity (PIRA) events.

Methods: A total of 362 pwMS (1,480 samples) starting BCDT in the Swiss Multiple Sclerosis (MS) Cohort were included. sGFAP levels in 2,861 control persons (4,943 samples) provided normative data to calculate adjusted Z scores.

Results: Elevated sGFAP levels (Z score >1) at 1 year were associated with a higher hazard for PIRA (hazard ratio [HR]: 1.80 [95% CI: 1.17-2.78]; p = 0.0079) than elevated sNfL levels (HR, 1.45 [0.95-2.24], p = 0.0886) in a combined model. Independent of PIRA events, sGFAP levels longitudinally increased by 0.49 Z score units per 10 years follow-up (estimate, 0.49 [0.29, 0.69], p < 0.0001). In patients experiencing PIRA, sGFAP Z scores were 0.52 Z score units higher versus stable patients (0.52 [0.22, 0.83], p = 0.0009). Different sNfL Z score trajectories were found in pwMS with versus without PIRA (interaction p = 0.0028), with an average decrease of 0.92 Z score units per 10 years observed without PIRA (-0.92 [-1.23, -0.60], p < 0.0001), whereas levels in patients with PIRA remained high.

Interpretation: Elevated sGFAP and lack of drop in sNfL after BCDT start are associated with increased risk of future PIRA. These findings provide a rationale for combined monitoring of sNfL and sGFAP in pwMS starting BCDT to predict the risk of PIRA, and to use sGFAP as an outcome in clinical trials aiming to impact on MS progressive disease biology. ANN NEUROL 2024.

Citing Articles

Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease.

Gomes A, Kim S, Pretzsch R, Kulsvehagen L, Schaedelin S, Lerner J Neurol Neuroimmunol Neuroinflamm. 2024; 12(1):e200347.

PMID: 39705633 PMC: 11666271. DOI: 10.1212/NXI.0000000000200347.

Tyro3 and Gas6 are associated with white matter and myelin integrity in multiple sclerosis.

Rosenstein I, Novakova L, Kvartsberg H, Nordin A, Rasch S, Rembeza E J Neuroinflammation. 2024; 21(1):320.

PMID: 39673059 PMC: 11645787. DOI: 10.1186/s12974-024-03315-0.

References

Ingwersen J, Masanneck L, Pawlitzki M, Samadzadeh S, Weise M, Aktas O . Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials. Sci Rep. 2023; 13(1):15003. PMC: 10495413. DOI: 10.1038/s41598-023-40940-w. View

Verkhratsky A, Butt A, Li B, Illes P, Zorec R, Semyanov A . Astrocytes in human central nervous system diseases: a frontier for new therapies. Signal Transduct Target Ther. 2023; 8(1):396. PMC: 10570367. DOI: 10.1038/s41392-023-01628-9. View

Barro C, Healy B, Saxena S, Glanz B, Paul A, Polgar-Turcsanyi M . Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. Mult Scler. 2022; 29(2):206-211. DOI: 10.1177/13524585221137697. View

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C . The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS One. 2016; 11(3):e0152347. PMC: 4816556. DOI: 10.1371/journal.pone.0152347. View

Wessels M, van Lierop Z, Noteboom S, Strijbis E, Heijst J, van Kempen Z . Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light. Mult Scler. 2023; 29(10):1229-1239. PMC: 10503252. DOI: 10.1177/13524585231188625. View

Hauser S, Bar-Or A, Weber M, Kletzl H, Gunther A, Manfrini M . Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023; 10(2). PMC: 9931184. DOI: 10.1212/NXI.0000000000200094. View

Muller J, Cagol A, Lorscheider J, Tsagkas C, Benkert P, Yaldizli O . Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review. JAMA Neurol. 2023; 80(11):1232-1245. DOI: 10.1001/jamaneurol.2023.3331. View

Kappos L, Traboulsee A, Li D, Bar-Or A, Barkhof F, Montalban X . Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2023; 271(2):642-657. PMC: 10827899. DOI: 10.1007/s00415-023-11943-4. View

Montalban X, Hauser S, Kappos L, Arnold D, Bar-Or A, Comi G . Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016; 376(3):209-220. DOI: 10.1056/NEJMoa1606468. View

10.

Hauser S, Bar-Or A, Comi G, Giovannoni G, Hartung H, Hemmer B . Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2016; 376(3):221-234. DOI: 10.1056/NEJMoa1601277. View

11.

Saraste M, Bezukladova S, Matilainen M, Sucksdorff M, Kuhle J, Leppert D . Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI. Mult Scler Relat Disord. 2021; 50:102810. DOI: 10.1016/j.msard.2021.102810. View

12.

Kappos L, DSouza M, Lechner-Scott J, Lienert C . On the origin of Neurostatus. Mult Scler Relat Disord. 2015; 4(3):182-5. DOI: 10.1016/j.msard.2015.04.001. View

13.

Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea R, Rahmanzadeh R . Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurol. 2022; 79(7):682-692. PMC: 9112138. DOI: 10.1001/jamaneurol.2022.1025. View

14.

Thebault S, Abdoli M, Fereshtehnejad S, Tessier D, Tabard-Cossa V, Freedman M . Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020; 10(1):10381. PMC: 7316736. DOI: 10.1038/s41598-020-67504-6. View

15.

Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R . Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018; 391(10127):1263-1273. DOI: 10.1016/S0140-6736(18)30475-6. View

16.

Kuhlmann T, Moccia M, Coetzee T, Cohen J, Correale J, Graves J . Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2022; 22(1):78-88. PMC: 10463558. DOI: 10.1016/S1474-4422(22)00289-7. View

17.

Teunissen C, Petzold A, Bennett J, Berven F, Brundin L, Comabella M . A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009; 73(22):1914-22. PMC: 2839806. DOI: 10.1212/WNL.0b013e3181c47cc2. View

18.

Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli O, Maceski A . Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022; 21(3):246-257. DOI: 10.1016/S1474-4422(22)00009-6. View

19.

Bar-Or A, Thanei G, Harp C, Bernasconi C, Bonati U, Cross A . Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023; 93:104662. PMC: 10320523. DOI: 10.1016/j.ebiom.2023.104662. View

20.

Abdelhak A, Benkert P, Schaedelin S, Boscardin W, Cordano C, Oechtering J . Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. JAMA Neurol. 2023; 80(12):1317-1325. PMC: 10628837. DOI: 10.1001/jamaneurol.2023.3997. View